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Abstract.  Exogenous transforming  growth factor beta 
(TGF-B1)  was shown in earlier studies to reversibly in- 
hibit mouse mammary ductal growth.  Using small 
plastic implants to treat regions of developing mam- 
mary glands in situ,  we now report that TGF-B1 
growth inhibition  is associated with an ectopic ac- 
cumulation of type I collagen messenger RNA and 
protein,  as well as the glycosaminoglycan, chondroitin 
sulfate.  Both macromolecules are normal components 
of the ductal extracellular matrix,  which,  under the 
influence of exogenous TGF-/31, became unusually 
Concentrated immediately adjacent to the epithelial 
cells at the tip of the ductal growth points, the end 
buds.  Stimulation of extracellular matrix  was confined 
to aggregations  of connective tissue cells around 
affected end buds and  was not present around the 
TGF-B1  implants themselves, indicating that the ma- 
trix effect was epithelium dependent.  Ectopic matrix 
synthesis was specific for TGF-B1 insofar as it was ab- 
sent at ducts treated with other growth inhibitors,  or 
at ducts undergoing normal  involution in response to 
endogenous regulatory processes. These findings are 
consistent with the matrix-stimulating  properties of 
TGF-/~I  reported for other systems, but differ in their 
strict dependence upon epithelium.  A  possible role for 
endogenous TGF-BI  in modulating a  mammary epithe- 
lium-stroma  interaction  is suggested. 
T 
RANSFORMING growth  factor beta-1  (TGF-/31)' and 
its receptors are ubiquitous in cells from both develop- 
ing  and mature  tissue,  and  the factor is capable of 
modulating  the growth and differentiation  of a wide variety 
of cell types (1, 16). TGF-B1 also stimulates the synthesis and 
deposition of extracellular  matrix  both in vivo and in vitro, 
as well as hastening wound healing by promoting the synthe- 
sis of fibrous connective tissue (15). A developmental  role 
for TGF-B1 is implied by its localization  in a variety of or- 
gans,  and by the finding that mesoderm induction  by fibro- 
blast growth factor in Xenopus embryos probably requires a 
TGF-B-Iike factor (11). In addition,  Mullerian inhibiting sub- 
stance (MIS), a peptide factor related to TGF-/31, causes the 
programmed resorption of the female urogenital  anlagen in 
fetal males (23). 
The mouse mammary ductal system grows by repeated, 
dichotomous branching  that  results  in  a  highly  arborated 
ductal tree connected at its base to the nipple (Fig.  1 a). Al- 
though most of this growth occurs postpartum it is, by sev- 
eral  criteria,  similar  to the embryonic morphogenesis  of 
branched organs such as the salivary gland, kidney, and lung, 
particularly with respect to the localization  and dynamics of 
extracellular  matrix,  which  develops adjacent to growth- 
1.  Abbreviations  used in  this paper:  ECM,  extracellular  matrix;  MIS, 
Mullerian  inhibiting  substance;  S-GAG, sulfated  glycosaminoglycans; 
TGF-BI, transforming growth factor-beta  1. 
points  (in the mammary gland,  the end buds) (2).  In each 
case the matrix  comprises collagens,  glycosaminoglycans, 
fibronectin,  laminin,  and proteoglycans (19, 24).  Both in 
vitro and in vivo studies have shown that growth and differen- 
tiation  of mammary ductal cells are dependent on the ex- 
tracellular  matrix  (3,  18). 
The  branching  growth  of mammary  ducts,  as  well  as 
growth inhibition,  involve a complex interplay of epithelium 
and mesenchyme that is characterized by the ongoing, highly 
localized replacement of fatty stroma by fibrous extracellular 
matrix  at the interface  of the two tissues (Fig.  1 c) (19, 20, 
24). This fibrous condensate forms along the end bud flanks 
and surrounds the narrowing  duct, giving rise to a collage- 
nous sheath that invests the entire ductal tree, with the excep- 
tion of the end bud tips, which, during active growth, are in- 
variably free of fibrous  investment.  This  organization  of 
fibrous connective  tissue is an example of a developmental 
tissue interaction,  as it is clear that the epithelium  induces 
the formation  of its stroma-derived fibrous tunic.  As with 
other  examples  of epithelium-mesenchyme  interaction  in 
branching morphogenesis,  the molecular signals responsible 
for regulating  the localization,  synthesis  and deposition of 
ductal extracellular  matrix are unknown. 
In other studies  (7, 21) we showed that localized  TGF-~I 
treatment  inhibited  mouse mammary ductal growth in situ. 
Terminal  ducts from glands treated for 4 d resembled un- 
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mal regulatory process,  suggesting that TGF-B1 may be a 
natural growth regulator in the gland (21). This suggestion 
is supported by the observation that whereas TGF-/31 rapidly 
and selectively inhibited ductal DNA synthesis, lobuloalveo- 
lar DNA synthesis was unaffected (7). The capacity of TGF- 
/31 to modulate the synthesis and deposition of extracellular 
matrix components in a variety of nonmammary systems, 
and the importance of the matrix in normal ductal growth, 
suggested that exogenous TGF-/31 might affect the ductal ex- 
tracellular matrix. Using plastic implants to treat mammary 
ducts in situ, we now report that short-term (12-24 h) treat- 
ment with TGF-/31 stimulated extensive extracellular matrix 
deposition that was localized at the end bud tip, a zone nor- 
mally free of fibrosis during active growth, suggesting a role 
for TGF-/31 as a  modulator of epithelium-stroma interac- 
tions. 
Materials and Methods 
Animals and Implants 
C57 females at 5 wk of age showing extensive end bud growth were used 
for these implant studies. Procedures for EVAc implant preparation and sur- 
gical implantation as well as alcian blue staining are described in detail else- 
where (21,  22). 
I~ssue Techniques 
For general histology glands were fixed for 12 h in either Tellyesniczky's 
or Carnoy's fixative. For whole mount preparations, glands were defatted 
for 3 h in three changes of acetone, stained 3 h with hematoxylin (0.65 g 
FeCI3; 67.5 ml water; 8.7 ml 10% hematoxylin in 95% ethanol;  1000 ml 
95%  ethanol,  pH  adjusted  to  1.25  with concentrated  HCI),  dehydrated 
through graded alcohols to xylene, and photographed. After whole-mount 
examination, pieces of tissue were embedded in paraffin and 5-#m sections 
were deparaffinized, rehydrated, and stained with alcian blue. The cationic 
dye, alcian blue, stains glycosaminoglycans and was used to demonstrate 
glycosaminoglycan-rich extracellular matrix as well as to delineate the epi- 
thelial-stromal boundary.  For simultaneous staining of both hyaluronate 
and sulfated glycosaminoglycans, the dye solution contained 0.1%  dye in 
0.025 M sodium acetate, pH 5.8, with 0.3 M MgCI2 (7). Staining time was 
45 rain. The prior hematoxylin stain did not affect this secondary staining. 
Sirius red F3BA (Mobay, Inc., Pittsburgh, PA), is an azo dye with high 
specificity for collagen. Tissue sections fixed as above were stained for 30 
rain in a mixture of 0.1% Sirius red and 0.1%  Fast Green, a counterstain, 
dissolved  in saturated  picric  acid  (12).  Digestion of sections  with  col- 
lagenase before staining eliminated Sirius red-stained material in the tissue 
(not shown). 
Three-dimensional Reconstructions 
Using a drawing attachment, the outlines of end buds and adjacent fibrous 
stroma were traced directly from microscope images of serial sections of 
treated and control end buds. Traced images were digitized using a digitiz- 
ing  pad  (Summagraphics),  and  reconstructed  using  three-dimensional 
reconstruction software developed  by The Laboratory  for High Voltage 
Electron Microscopy,  University of Colorado. 
Sulfated Glycosaminoglycan Synthesis 
Autoradiographic localization of sulfated glycosaminoglycans has been de- 
scribed by  us  in detail  (19).  Briefly,  carrier-free  H2SO4  is  injected  in- 
traperitoneally and 3 h later the animal is killed. Tissue is then fixed and 
sectioned  and  autoradiography  is  carried  out  using  standard  methods. 
Chondroitinase ABC (Sigma Chemical Co., St. Louis, MO) (2.5 U/ml in 
0.1 M Tris HCI, pH 8.0, 37°C for 4 h) was used on sectioned material to 
determine the extent of sulfur incorporation into chondroitin sulfate. 
In Situ Hybridization 
Probe. A  1.3-kb fragment containing the coding region for rat alpha 1 (I) 
collagen  (isolated by  Dr.  David  Rowe,  University of Connecticut)  was 
cloned by Dr. Steven Feitelberg (University of California, San Diego) into 
an SP6/T7 plasmid (pGEM, Promega Biotec, Madison, WI). High specific 
activity sense (control) and antisense RNA probes using [35S]UTP (1,200 
Ci/mmol) were made using Promega Biotec transcription reaction protocol 
no.  1. Probes were sized by limited alkaline hydrolysis to "~150 bp. 
1Issue. A modification of the Cox et al. hybridization protocol was fol- 
lowed (6).  Briefly,  tissue was fixed in 4%  paraformaldehyde for 3 h, de- 
hydrated through graded alcohols to xylene and paraffin embedded;  10-~m 
sections were deparaffinized and pretreated with  i.0%  BSA, followed by 
0.2 N HCI, then digested with 1 ~g/ml proteinase K (in 20 mM Tris, 2 mM 
CaCI, pH 7.5), to improve probe access.  Sections were then postfixed in 
4% paraformaldehyde, blocked with 0.2 % glycine and treated with 0.25 % 
acetic anhydride in 0.1 M triethanolamine to acetylate positive charges on 
the slide or tissue. 
Blocking Probes. Using a variety of antisense probes, including that for 
type I collagen, we observed heavy, nonspecific hybridization in the con- 
densed stroma around treated and control end buds. This problem was over- 
come by adding a blocking hybridization step utilizing "irrelevant," cold 
mRNA transcripts. For convenience, we used the three transcripts gener- 
ated by T7 polymerase from the Promega phage lambda "control templates" 
(1.38, 0.55, and 0.22 kb, respectively). Each slide was incubated with 4/~g 
of lambda mRNA in hybridization buffer (see below) for 16 h at 56°C. After 
incubation, slides were washed in four changes of 2 x  SSC for 1 h and air 
dried before proceeding. 
Hybridization. To each slide, i  x  106 cpm were added in 40 #1 hybrid- 
ization buffer (50% formamide, 300 mM NaCI, 10 mM Tris, 1 mM EDTA, 
lx  Denhardt's, 10% PEG,  100 mM DTT, 25 U RNasin [Promega Biotec] 
and  150 ~g/ml tRNA);  incubation was overnight at 56°C with coverslips 
sealed with rubber cement to prevent changes in hybridization volume. All 
posthybridization washes contained DTT.  Slides were washed in 2x  SSC 
containing 50 mM  DTT,  treated with 20 #g/ml  RNase  A  (Calbiochem- 
Behring Corp.,  La Jolla, CA), 30 min, 37°C,  (without DTT),  washed in 
RNase buffer (with 5 mM DTT), 5 liters 2x  SSC (with 1 mM DTT), 50% 
formamide in 2x  SSC,  1% SDS (with 1 mM ITI'T) at 50°C for 1 h and at 
65°C for 5 rain and a final wash of2x  SSC for 5 rain. Slides were air-dried 
and dipped in NTB-2 emulsion diluted 1:1 with water. Slides were exposed 
for 2 d and developed in D-19 developer. 
Control  I~ssue. On each slide there were sections of 5-wk mammary 
gland that had been implanted for 24 h with 120 ng TGF-~I as well as sec- 
tions of control gland treated with nonreactive BSA. Longitudinal sections 
of (15-d) mouse embryo were included on each slide and showed specific 
localization of collagen 1 message in chondrocytes and skin (not shown). 
Results 
In mammary gland branching morphogenesis, the tips of 
rapidly growing ducts are enlarged, forming highly mitotic, 
bulbous  end  buds  (Fig.  1,  a  and  c).  A  basal  epithelial 
monolayer consisting of myoepithelial stem cells, the cap 
cells, overlays the body of the end bud; during ductal growth 
these cells are normally apposed to adipocytes (Fig. 1 c). In 
response to  exogenous TGF-BI,  end buds are  rapidly re- 
placed by nonproliferating ductal tips (Fig.  1 b).  Earlier 
studies had shown that after 4 d, TGF-Bl-treated ducts were 
morphologically similar to ducts from untreated, growth- 
quiescent glands with respect to epithelial histo-architecture 
particularly the differentiation  of the cap cells. The organiza- 
tion of  adjacent fibrous connective tissue at 4 d was also simi- 
lar in treated and control tissue (21). 
Early Effects of TGF-{31 Treatment on Collagen 
Gene Expression 
Recent in vitro experiments have shown that TGF-/~I stimula- 
tion of collagen and fibronectin mRNA synthesis in mouse 
3T3 cells occurs within a narrow time-frame of 12-24 h after 
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 Figure 2. Localization of type I collagen mes- 
sage by in situ hybridization.  (a and b) Light- 
and dark-field micrographs of  an end bud in the 
vicinity ofa TGF-/31 implant (150 rig) for 24 h. 
Cellular  connective tissue (arrow) and heavy 
hybridization are apparent over the tip of the 
end bud. (c and d) Light- and dark-field micro- 
graphs  of an untreated  end bud.  There is no 
labeling  over the tip except where  a  cleft  is 
forming  (arrow). Both treatment  and control 
tissues showed similar levels of labeling over 
the flanks and subtending duct.  (e) Tissue ex- 
posed to sense mRNA probe. End bud (arrow) 
had  slightly higher  than background  labeling 
but no specific localization was observed. Bar, 
50 t~m. 
treatment  (13),  suggesting the  importance of investigating 
effects of TGF-/31 occurring before the 4-d time period of our 
earlier report (21).  To carry out this study we treated ducts 
in 5-wk, virgin animals for 24--48 h  with doses of TGF-/~I 
known to  inhibit growth,  and examined effects on the ex- 
tracellular matrix. 
Type I collagen, a dominant component of fibrous matrix, 
is normally associated with the periductal matrix but does 
not occur in quantity around the tips of growing end buds (19, 
24). Using antisense mRNA from the rat alpha 1(I) collagen 
gene for in situ hybridization, we examined collagen gene ex- 
pression  around  untreated  end buds  and those treated for 
24 h in situ with TGF-B1.  In treated glands, heavy labeling 
was usually found in stroma adjacent to the cap cell layer at 
the growing tip (Fig. 2 b), and was typically organized into 
one or more conspicuous strands extending ahead of the end 
bud tip into the stroma. Histologically, the collagen message 
colocalized with a conspicuous structure consisting of fibro- 
cytes and alcianophilic matrix (Fig,  2  a). 
In untreated  glands there was heavy collagen I  gene ex- 
pression on the end bud flank and subtending duct, whereas 
only background levels were observed at the end bud tips 
The Journal of Cell Biology, Volume 110, 1990  2212 Figure 3. Photomicrographs illustrating 
the effects of TGF-~I  (150 ng/15 h) on 
collagen distribution around an end bud 
and adjacent implant (a);  control duct 
(b).  Bar, 50 #m.  Tissue sections were 
stained with the collagen-specific dye, 
Sirius red (see Materials and Methods). 
The periductal  collagenous sheath ap- 
peared to stain more heavily in the TGF- 
/~l-treated duct (arrow),  less so in the 
control. In the treated gland, some stain 
was  visible  within the  dense,  cellular 
mass adjacent to the end bud tip. Note 
the absence of stain or dense cellularity 
around  the  TGF-#I  implant  (*). The 
heavily stained fibers beneath the con- 
trol duct are part of collagenous septae, 
a normal feature of the gland. 
(Fig. 2, c and d). Treated tissue showed the same pattern of 
labeling in the flank and subtending duct as the control (Fig. 
2, b and d), indicating that treatment did not influence the 
expected high level ofperiductal collagen gene transcription. 
To  determine  if gene  expression  was  accompanied  by 
deposition  of collagen  fibers,  TGF-~l-treated  tissue  was 
stained with the collagen-specific dye, Sirius red (Fig. 3 a). 
A few fibers of deeply stained collagen were visible in the 
dense cellular mass over the end bud tip, but most of the ma- 
trix stained lightly and appeared amorphous. The absence of 
conspicuous stain around the TGF-B1 implant and between 
the duct tip and the implant was noted. Untreated gland, in 
which end buds were involuting due to normal regulatory 
processes, showed only a thin layer of Sirius red staining at 
the tip (Fig.  3 b). 
Tissue sections passing through the plastic implants were 
examined and no organized areas of increased collagen gene 
activity were observed around either the TGF-~I or the con- 
trol  implants  (Fig.  4).  Scattered  foci of collagen  mRNA 
synthesis were found throughout the stroma, in a punctate 
pattern similar to that described for the skin (17). Thus, orga- 
nized areas  of intense  mRNA  synthesis occurred only in 
stroma at the end bud tip in TGF-/~l-treated gland, and in a 
periductal location in all glands, and therefore appeared to 
be unrelated to placement of the TGF-~  implant.  As ex- 
pected, no labeling above background was  found over any 
mammary epithelial tissues. 
TGF-[31 Effects on Synthesis of 
Sulfated Glycosaminoglycans 
Sulfated glycosaminoglycans (S-GAG)  are  constituents of 
matrix proteoglycans, and  are a  major component of the 
periductal matrix (19, 20). TGF-~'I has been shown to induce 
chondroitin sulfate synthesis in mammary cells in vitro (14). 
Staining with the cationic dye alcian blue indicated heavy ac- 
cumulations of S-GAG at the tip of TGF-~l-treated end buds 
(Fig. 5 a) (19, 20). To investigate the biosynthesis of S-GAG, 
radiolabeled sulfur incorporation was studied.  The stroma 
around TGF-/~I affected end buds showed extensive 35S in- 
Silberstein et al. TGFBI and Mammary Gland Matrix Synthesis  2213 Figure 4.  In situ localization of 
type I collagen message in tissue 
adjacent to (a) BSA-containing  or 
(b)  TGF-/~l-containing implant 
(dotted line marked implant  bound- 
ary).  TGF-#I  did  not  induce a 
me~  capsule around 
the implant. Scattered foci of hy- 
bridization appear in the adipose 
tissues  in  approximately  equal 
numbers  in  treatment  and  con- 
trol. The density of the focal sig- 
nals appeared greater in the TGF- 
El-treated  gland  pictured  here, 
though this was not consistently 
observed. Bar, 50/~m. 
corporation, extending well beyond the end bud tip. In sec- 
tions of TGF-/~l-treated end buds  digested with chondroi- 
tinase ABC, a significant amount of label was removed (Fig. 
6), indicating that much of the incorporated sulfur was con- 
tained in chondroitin sulfates.  The heavy incorporation of 
3sS in the stroma, the low level of labeling over the epithe- 
lium, and the relatively short labeling time, suggest that the 
bulk of the labeled molecules were synthesized directly in 
the stroma and not transported from the epithelium. 
In  contrast  to  the  TGF-/ffl-affected  tissues,  control end 
buds showed only light alcian blue staining above the cap 
zone,  with characteristically heavy staining  on the flanks 
and subtending ducts (Fig. 5 c); 35S was concentrated in the 
latter zone and was only lightly deposited on the caps (Fig. 
5 d). 
TGF-~I enhancement of S-GAG synthesis was also found 
to be mediated by mammary epithelium.  Examination of 
TGF-/~I implants showed no accumulation of alcianophilic 
material in surrounding stroma, and there was no stimulation 
of sulfur incorporation on the border of the TGF-~I implants 
(Figs.  5 and 6). 
Effect of Growth Inhibition on Ductal ECM 
The observation of intense ECM synthesis at TBF-~l-inhib- 
ited end bud tips left open the question of specificity of ac- 
tion.  We were interested  in determining if the  effect was 
specific to exogenous TGF-/~I or, alternatively, if growth in- 
hibition and matrix synthesis may be tightly coupled and, 
whether achieved by TGF-ffl or another growth inhibitor, in- 
evitably results in heavy matrix deposition over the end bud 
tip. 
Comparing normally involuted and TGF-/31-treated ducts, 
heavy matrix concentrations were never seen at the ductal 
tips in untreated glands (Figs. 7, a  and b and reference 19). 
Three  dimensional  reconstructions  of  matrix  disposition 
demonstrated that  even in  the  early  stages  of involution, 
where the end bud shape is still evident, the extracellular ma- 
trix merely envelopes the tip of the untreated end bud rather 
than extending far beyond it (Fig. 7, d  and e). 
To investigate the possibility that inhibition of epithelial 
DNA  synthesis by other exogenous agents could result in 
heavy matrix accumulation over the end bud tip, inhibitors 
other than TGF-~'I  were tested. Implantation of EGF pro- 
duced localized inhibition of end bud growth (5), but in no 
case  were  heavy  ectopic  matrix  accumulations  observed 
(Fig. 7 c). Implanted dexamethasone, another reversible in- 
hibitor of ductal growth, also did not lead to unusual matrix 
accumulation (not shown). 
Discussion 
Matrix-inducing  properties  of TGF-/~I  are  now  well  de- 
scribed and are characterized by the rapid and coordinated 
synthesis of many matrix elements, including type I collagen 
and chondroitin sulfate, by cultured cells, as well as by the 
inhibition of synthesis of matrix-degrading enzymes (15). In 
this paper we show that within 24--48  h, growth inhibition 
by implanted TGF-~I was associated with highly localized, 
intense collagen I gene expression and synthesis of sulfated 
glycosaminoglycans (Figs. 2, 3, 5, and 6). This stromal re- 
sponse occurred in an unusual location, ahead of the end 
bud, and thus differed from the progressive investment of the 
tip by extracellular matrix extending up the sides of the end 
bud that occurs in normal involution or in response to growth 
inhibitors such as EGF or dexamethasone (Fig. 7) (5, 20). 
The use of plastic implants to administer TGF-/~I in situ 
permitted us to distinguish between matrix formation that 
was a response to epithelium-stroma interactions, and gen- 
eralized induction of stromal matrix elements.  Short-term 
treatment with TGF-BI did not result in intense matrix syn- 
thesis at the site of the implant; instead, matrix often formed 
up to a millimeter away from the implant and was confined 
to a zone at the tip of the end bud epithelium. 
The action of TGF-/~I on matrix synthesis clearly required 
The Journal of Cell Biology,  Volume 110, 1990  2214 Figure 5. Photomicrographs of alcian blue stained, 35S autoradiographs showing incorporation of radiolabeled  sulfur into TGF-~/1 treated 
(150 ng/24 h) and untreated  tissue. Light (a and c) and dark-field  (b and d) micrographs are shown.  (a and b) TGF El-treated  gland. Note 
the heavy concentration of label  around the tip of the end bud. (Arrow indicates  epithelial-stromal  interface.)  Implant is at upper right 
and is indicated  by asterisk in a and a boundary of white dots in b. (c and d) Control. Note the heavy concentration of label on the end 
bud flank (arrow) and subtending  duct and the lighter labeling on the tip. In all cases, labeling colocalized with alcianophilia.  Bar, 50/~m. 
Silberstein et al. TGFBI and Mammary Gland Matrix Synthesis  2215 Figure  6.  Photomicrographs of 3~S autoradiography show- 
ing the effect of chondroitinase ABC digestion of sections of 
mammary gland in the vicinity of a TGF-/31 implant (150 
ng/24 h).  (a) Alcian blue-stained section showing two end 
buds (the topmost seen in cross-section) adjacent to a TGF- 
/~ 1 implant (*). (b) Section incubated for 4 h in digest buffer 
minus enzyme. Silver grains are concentrated in the matrix 
at the epithelial-stromal interface closest to the implant (ar- 
rows); the implant border is bounded by white dots. (c) Sec- 
tion adjacent to that pictured in b, digested for 4 h had ,050 % 
fewer silver grains between the epithelial-stromal  boundary 
of the end bud (arrows) and the implant. Similar results were 
obtained by  digesting with  testicular hyaluronidase.  Bar, 
50 #m. 
The Journal of Cell Biology, Volume 110, 1990  2216 Figure  7. Comparison of pattern of extracellular matrix deposition around TGF-/51- and EGF-affected end buds with normally involuted 
duct tips. (a) End bud treated for 24 h with 150 ng TGF-B1. Arrow points to the epithelial-mesenchymal interface. (b) Tip of normally 
involuting duct. Note the approximately even thickness of the fibrous investment on the duct sides and around the tip. (c) End bud treated 
with EGF (21 #g/72 h). At 3 d, EGF treatment resulted in an 85% reduction in DNA synthesis as determined by thymidine autoradiography 
with end bud involution following  at later time-points (5). Bar in a, b, and c, 50 #m). (d and e) Three-dimensional computer reconstructions 
of treated and control end buds emphasize the matrix induced by TGF-BI. End buds are different than those pictured in a and b. Fibrous 
stroma is represented by the unshaded zones surrounding the (gray) end buds. 
the participation of adjacent epithelium. Two hypotheses are 
suggested.  First,  the action of exogenous TGF-B1  may be 
directly on the mammary epithelium, inhibiting cell prolifer- 
ation as  previously reported (21),  but not stimulating  in- 
creased matrix synthesis per se. Here, the growth-inhibited 
epithelium organizes the surrounding stromal cells, which 
are already engaged in ECM synthesis, to form a periductal 
investment when  the epithelium fails  to continue its  out- 
growth. 
This suggestion explains the absence of organized ECM 
synthesis around the TGF-/31 implant,  and is Supported by 
the observation that scattered stromal cells exhibit a consid- 
erable degree of background ECM synthesis (Figs. 2, b and 
d, and 6 b).  The notion of mammary epithelium as an or- 
ganizational center is also supported by histological studies 
on which the three-dimensional reconstructions were based 
(Fig. 7), in which it frequently appeared that stromal ceils 
were aligned in "streams  7 perhaps responding to chemotac- 
tic signals from the inhibited epithelium. A purely inhibitory 
role for exogenous TGF-B1 is not consistent, however, with 
the  observation that  intense,  ectopic  ECM  synthesis  was 
present only in TGF-Bl-treated gland, and was not observed 
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treatment with exogenous EGF or dexamethasone (Fig. 7). 
A second hypothesis is that, in addition to exogenous TGF- 
HI, an unknown diffusible factor of epithelial  origin is re- 
quired to stimulate periductal extracellular matrix synthesis 
and deposition. A diffusible factor is considered more likely 
than signaling through cell-cell  contacts,  because the basal 
lamina around the end bud and duct is continuous, and con- 
tacts between epithelial and stromal cells have not been ob- 
served (24). 
A  putative epithelial  factor might operate by sensitizing 
nearby mesenchymal cells to respond to TGF-/31, which then 
stimulates ECM synthesis. The unusual amounts of TGF-/~I 
released by the implant could result in the observed ectopic 
ECM synthesis.  Alternatively,  the epithelium could release 
a  factor  in  response  to  TGF-/31 that  directly  stimulated 
stromal synthesis of matrix components. Either model would 
account for the epithelial requirement of TGF-/31 action and 
would explain the absence of matrix stimulation around the 
implant. 
The epithelium requirement for mammary ECM synthesis 
in response to TGF-~I contrasts with several in vitro studies 
which,  with limited exceptions (8, 9),  show TGF-~I  to be 
capable of stimulating the synthesis of extracellular matrix 
components unassisted (15). While some of these results may 
reflect the adaptation of cells to long-term culture, TGF-/31 
also enhanced the synthesis of glycosaminoglycan in primary 
cultures treated soon after isolation (4, 25). These results in- 
dicate tissue- and cell-specific  requirements for stimulation 
of matrix synthesis. 
The condensation of fibrocytes and the synthesis of matrix 
around mammary epithelium is similar in certain respects to 
epithelial-mesenchymal  interactions in the developing male 
urogenital tract that lead to the programmed involution of the 
female urogenital anlagen (23).  In this case, testicular Ser- 
toli cells  synthesize  Mullerian  inhibiting substance (MIS), 
which induces the aggregation of mesenchymal cells and the 
deposition of a chondroitin sulfate-rich extracellular matrix 
around the female epithelial anlagen.  Ductal resorption fol- 
lows. As with the mammary results reported here, the MIS 
effect is exquisitely localized, and the mesenchymal response 
is clearly  organized by the epithelium. 
These similarities between the mammary gland and Mul- 
lerian duct suggest that TGF-/31, or molecules with similar 
activities,  may normally act in conjunction with tissue-spe- 
cific agents in a variety of developing tissues to mediate epi- 
thelial-mesenchymal  interactions.  This notion is supported 
by the immunohistochemical localization of TGF-/31 in num- 
erous mouse embryonic  tissues at sites where epithelium- 
mesenchyme interactions are occurring (10). 
Our results, showing specific action of TGF-/31 on epithe- 
lium-dependent ECM synthesis in vivo, may be helpful in in- 
terpreting recent data showing the presence of endogenous 
TGF-/31  in  mammary  ducts  and their  surrounding stroma 
(Daniel et al., unpublished). In our present study, the ectopic 
location of ECM synthesis was unusual, due presumably to 
the mode of growth factor delivery in which abnormal con- 
centrations of the growth factor were delivered at the end bud 
tip.  Nevertheless,  the  demonstrated  ability  of TGF-/~I  to 
stimulate ECM in a specific, epithelium-dependent manner, 
suggests a role for endogenous TGF-131 in the organization 
of periductal stroma, perhaps by mediating an epithelium- 
stroma interaction. 
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